Despite the above limitations, the majority of prostate tumors retain functional AR signalling and wild type p53, so we propose that prostate cancer could represent an ideal setting in which to make a clinical assessment of p53-MDM2 antagonists. This evidence concerns the gene TP53 and prostate cancer.